Scholarlink

Background <p>Glucagon-like peptide 1 (GLP-1) analogues are a class of medications that stimulate glucose-dependent insulin release and slow gastric emptying. With the increasing use of GLP-1 analogues, concerns about potential psychiatric adverse events (AEs) remain under-explored.</p> Aim <p>This pharmacovigilance study aimed to investigate the prevalence of psychiatric AEs associated with currently available GLP-1 analogues by analysing publicly available national datasets from the US (FAERS), Canada (CVAROD) and Australia (DAEN).</p> Method <p>Psychiatric AE reports were extracted from all three databases for all approved GLP-1 analogues. A disproportionality analysis was conducted to calculate reporting odds ratios (RORs) and 95% confidence intervals (CIs) for psychiatric AEs of interest.</p> Results <p>Significant associations were identified when multiple databases reported elevated RORs. Semaglutide was associated with depressive symptoms (FAERS, ROR = 6.24 CI 4.49–8.69), panic attacks (FAERS, ROR = 1.46 CI 1.16–1.82) and suicidal ideation (FAERS, ROR = 2.58 CI 2.31–2.88). Liraglutide was linked to depression (CVAROD, ROR = 1.68 CI&#xa0;1.12–2.51), while dulaglutide showed positive associations with eating disorders (FAERS, ROR = 1.47 CI 1.26–1.71) and insomnia (FAERS, ROR = 2.93 CI 2.35–3.66).</p> Conclusion <p>GLP-1 analogues, particularly semaglutide and liraglutide, are associated with significant psychiatric AEs, especially depression and suicidal ideation. Further studies are required to understand the mechanisms underlying these associations, particularly in patients with pre-existing psychiatric conditions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月16日

查看全文
  • Jonah Katranski,
  • Sihua Liang,
  • Deirdre Morris,
  • Vijayaprakash Suppiah,
  • Chiao Xin Lim

摘要

Background

Glucagon-like peptide 1 (GLP-1) analogues are a class of medications that stimulate glucose-dependent insulin release and slow gastric emptying. With the increasing use of GLP-1 analogues, concerns about potential psychiatric adverse events (AEs) remain under-explored.

Aim

This pharmacovigilance study aimed to investigate the prevalence of psychiatric AEs associated with currently available GLP-1 analogues by analysing publicly available national datasets from the US (FAERS), Canada (CVAROD) and Australia (DAEN).

Method

Psychiatric AE reports were extracted from all three databases for all approved GLP-1 analogues. A disproportionality analysis was conducted to calculate reporting odds ratios (RORs) and 95% confidence intervals (CIs) for psychiatric AEs of interest.

Results

Significant associations were identified when multiple databases reported elevated RORs. Semaglutide was associated with depressive symptoms (FAERS, ROR = 6.24 CI 4.49–8.69), panic attacks (FAERS, ROR = 1.46 CI 1.16–1.82) and suicidal ideation (FAERS, ROR = 2.58 CI 2.31–2.88). Liraglutide was linked to depression (CVAROD, ROR = 1.68 CI 1.12–2.51), while dulaglutide showed positive associations with eating disorders (FAERS, ROR = 1.47 CI 1.26–1.71) and insomnia (FAERS, ROR = 2.93 CI 2.35–3.66).

Conclusion

GLP-1 analogues, particularly semaglutide and liraglutide, are associated with significant psychiatric AEs, especially depression and suicidal ideation. Further studies are required to understand the mechanisms underlying these associations, particularly in patients with pre-existing psychiatric conditions.